麻豆传媒

In randomized study, ensartinib doubled PFS versus first-generation ALK inhibitor

Signal largely driven by newly emerging arrhythmias

Prevention and screening efforts accounted for 80% of those averted deaths

Unprecedented 22.5-month improvement in median overall survival as consolidation therapy

Zenocutuzumab achieved response rates of 40% in pancreatic adenocarcinoma, 33% in advanced NSCLC

A look back at some of the newsworthy developments of 2024

Largest survival benefit observed in patients who entered a cessation program within 6 months

Debate highlights pros and cons of the new recommendation

Osimertinib plus ramucirumab in first line shows 9-month PFS advantage over EGFR inhibition alone

Study raises questions about how to assess patient risk, experts say

Latest negative results emphasize "critical" aspect of immunotherapy timing